HK1245653A1 - 藥物製劑 - Google Patents

藥物製劑

Info

Publication number
HK1245653A1
HK1245653A1 HK18105201.4A HK18105201A HK1245653A1 HK 1245653 A1 HK1245653 A1 HK 1245653A1 HK 18105201 A HK18105201 A HK 18105201A HK 1245653 A1 HK1245653 A1 HK 1245653A1
Authority
HK
Hong Kong
Prior art keywords
pharmaceutical formulation
formulation
pharmaceutical
Prior art date
Application number
HK18105201.4A
Other languages
English (en)
Inventor
Mahendra G Shah
Original Assignee
Semnur Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Semnur Pharmaceuticals Inc filed Critical Semnur Pharmaceuticals Inc
Publication of HK1245653A1 publication Critical patent/HK1245653A1/zh

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/661Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0085Brain, e.g. brain implants; Spinal cord
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/04Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/06Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
HK18105201.4A 2015-01-21 2018-04-20 藥物製劑 HK1245653A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562106045P 2015-01-21 2015-01-21
PCT/US2016/014165 WO2016118649A1 (en) 2015-01-21 2016-01-20 Pharmaceutical formulation

Publications (1)

Publication Number Publication Date
HK1245653A1 true HK1245653A1 (zh) 2018-08-31

Family

ID=55405453

Family Applications (2)

Application Number Title Priority Date Filing Date
HK18103436.6A HK1243932A1 (zh) 2015-01-21 2018-03-12 藥物製劑
HK18105201.4A HK1245653A1 (zh) 2015-01-21 2018-04-20 藥物製劑

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HK18103436.6A HK1243932A1 (zh) 2015-01-21 2018-03-12 藥物製劑

Country Status (14)

Country Link
US (4) US10500284B2 (zh)
EP (2) EP3925597A1 (zh)
JP (4) JP6829201B2 (zh)
KR (2) KR20230157534A (zh)
CN (2) CN107205926B (zh)
AU (1) AU2016209332B2 (zh)
BR (1) BR112017015452B1 (zh)
CA (1) CA2974657C (zh)
ES (1) ES2877371T7 (zh)
HK (2) HK1243932A1 (zh)
IL (1) IL253570B (zh)
MX (2) MX2017009482A (zh)
TW (3) TWI674899B (zh)
WO (1) WO2016118649A1 (zh)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2948182B1 (en) 2013-01-23 2020-09-30 Semnur Pharmaceuticals, Inc. Pharmaceutical formulation comprising an insoluble corticosteroid and a soluble corticosteroid
TWI674899B (zh) 2015-01-21 2019-10-21 美商桑紐爾製藥公司 醫藥配方
AU2016269847A1 (en) * 2015-06-02 2017-12-07 Intravital Pty Ltd Drug delivery device with pre-assembled cartridge
CN112870155B (zh) * 2021-03-08 2023-06-30 上海昱聚科技有限公司 缓释地塞米松药物的凝胶注射剂及其制备方法和应用

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL25251A (en) 1965-07-20 1969-11-12 Merck & Co Inc Aqueous mixtures for ophthalmology based on hydroxyethylcellulose and a method for their preparation
US3962430A (en) 1974-08-07 1976-06-08 Merck & Co., Inc. Sterilization of solid non-electrolyte medicinal agents employing sodium chloride
US4304765A (en) 1980-10-14 1981-12-08 Alza Corporation Ocular insert housing steroid in two different therapeutic forms
EP0244178A3 (en) 1986-04-28 1989-02-08 Iolab, Inc Intraocular dosage compositions and method of use
IL80298A (en) * 1986-10-14 1993-01-31 Res & Dev Co Ltd Eye drops
FI105075B (fi) 1996-01-10 2000-06-15 Suprakort Oy Kombinaatioinjektiovalmisteen käyttö
IT1288290B1 (it) 1996-06-21 1998-09-11 Fidia Spa In Amministrazione S Acido ialuronico autoreticolato e relative composizioni farmaceutiche per il trattamento delle artropatie
JPH11279065A (ja) * 1998-03-25 1999-10-12 Shiseido Co Ltd 局所投与炎症治療剤
US6921532B1 (en) 2000-06-22 2005-07-26 Spinal Restoration, Inc. Biological Bioadhesive composition and methods of preparation and use
US6747090B2 (en) 2001-07-16 2004-06-08 Pharmacia Groningen Bv Compositions capable of forming hydrogels in the eye
US20040006052A1 (en) 2002-04-15 2004-01-08 Gudas Charles J. Injection solutions to treat neuropathic symptoms and other sensorimotor disorders that are due to neuromas of the foot or other entrapment neuropathies of peripheral nerves, and method of use
CN101094690A (zh) * 2003-11-12 2007-12-26 阿勒根公司 用于治疗眼后节的组合物及方法
US20070224278A1 (en) 2003-11-12 2007-09-27 Lyons Robert T Low immunogenicity corticosteroid compositions
US20050186229A1 (en) * 2004-02-24 2005-08-25 Emmett Clemente Pleasant-tasting aqueous liquid composition of prednisolone sodium phosphate
JP2007001926A (ja) * 2005-06-24 2007-01-11 Ltt Bio-Pharma Co Ltd 吸入・噴霧用ステロイド製剤
JP4969812B2 (ja) 2005-07-22 2012-07-04 久光製薬株式会社 ハイドロゲル組成物
US20070099882A1 (en) 2005-10-27 2007-05-03 Gurney Harry C Methods and compositions for prolonged alleviation of articular joint pain
US20070203095A1 (en) * 2005-12-14 2007-08-30 Anika Therapeutics, Inc. Treatment of arthritis and other musculoskeletal disorders with crosslinked hyaluronic acid
CN100534434C (zh) 2006-05-15 2009-09-02 西安力邦制药有限公司 透明质酸钠地塞米松脂肪乳制剂及其应用
WO2008057364A1 (en) * 2006-11-02 2008-05-15 Riolan Technologies, Inc. Method for treating blepharitis
US20080317805A1 (en) 2007-06-19 2008-12-25 Mckay William F Locally administrated low doses of corticosteroids
US9421356B2 (en) * 2007-08-28 2016-08-23 Teikoku Pharma Usa, Inc. Transdermal methods and systems for the delivery of corticosteroid compounds
US20090143348A1 (en) 2007-11-30 2009-06-04 Ahmet Tezel Polysaccharide gel compositions and methods for sustained delivery of drugs
US20090143807A1 (en) 2007-12-03 2009-06-04 Vertos Medical, Inc., A Delaware Corporation Percutaneous Devices for Separating Tissue, Kits and Methods of Using the Same
JP2011513337A (ja) 2008-04-18 2011-04-28 ウォーソー・オーソペディック・インコーポレーテッド 椎間板ヘルニアを治療するための方法および組成物
MX2010012397A (es) 2008-05-14 2011-03-15 Otonomy Inc Star Composiciones de corticosteroides de liberacion controlada y metodos para el tratamiento de transtornos oticos.
CN101683532A (zh) * 2008-09-25 2010-03-31 武汉诺安药业有限公司 含玻璃酸或其盐的眼用复方药物制剂
EP2365812A4 (en) 2008-11-10 2012-05-16 Nitric Biotherapeutics Inc PHARMACEUTICAL FORMULATIONS FOR THE IONTOPHORETIC DELIVERY OF A CORTICOSTEROID
UA111162C2 (uk) 2010-08-04 2016-04-11 Флекшен Терап'Ютікс, Інк. Ін'єкційна композиція ацетоніду триамцинолону для лікування болю
RU2459615C1 (ru) * 2011-03-05 2012-08-27 Илья Александрович Марков Глазные капли для лечения болезни сухого глаза
MX2014006056A (es) * 2011-12-06 2014-08-08 Alcon Res Ltd Composicion de gel de celulosa con una mejor estabilidad de la viscosidad.
US20130165419A1 (en) 2011-12-21 2013-06-27 Insite Vision Incorporated Combination anti-inflammatory ophthalmic compositions
EP2948182B1 (en) 2013-01-23 2020-09-30 Semnur Pharmaceuticals, Inc. Pharmaceutical formulation comprising an insoluble corticosteroid and a soluble corticosteroid
TWI674899B (zh) 2015-01-21 2019-10-21 美商桑紐爾製藥公司 醫藥配方

Also Published As

Publication number Publication date
CA2974657A1 (en) 2016-07-28
CN107205926A (zh) 2017-09-26
EP3247329A1 (en) 2017-11-29
US20180008714A1 (en) 2018-01-11
EP3247329B1 (en) 2021-05-19
HK1243932A1 (zh) 2018-07-27
CN112957320A (zh) 2021-06-15
CN107205926B (zh) 2021-03-05
IL253570A0 (en) 2017-09-28
TWI674899B (zh) 2019-10-21
IL253570B (en) 2020-08-31
US10117938B2 (en) 2018-11-06
JP2021183649A (ja) 2021-12-02
JP2021143209A (ja) 2021-09-24
ES2877371T3 (es) 2021-11-16
JP2020073576A (ja) 2020-05-14
TWI772659B (zh) 2022-08-01
JP2018502872A (ja) 2018-02-01
KR20170103974A (ko) 2017-09-13
MX2021012029A (es) 2021-10-26
BR112017015452B1 (pt) 2022-11-08
JP7269992B2 (ja) 2023-05-09
WO2016118649A1 (en) 2016-07-28
US10500284B2 (en) 2019-12-10
US20210386859A1 (en) 2021-12-16
TW201630609A (zh) 2016-09-01
US20200197523A1 (en) 2020-06-25
US11020485B2 (en) 2021-06-01
CA2974657C (en) 2024-02-20
MX2017009482A (es) 2017-11-15
KR20230157534A (ko) 2023-11-16
AU2016209332A1 (en) 2017-09-07
JP6829201B2 (ja) 2021-02-10
KR102600792B1 (ko) 2023-11-10
EP3925597A1 (en) 2021-12-22
TW202005652A (zh) 2020-02-01
EP3247329B3 (en) 2022-02-09
BR112017015452A2 (pt) 2018-01-23
US20180185494A1 (en) 2018-07-05
JP7065129B2 (ja) 2022-05-11
ES2877371T7 (es) 2022-05-24
TW202245791A (zh) 2022-12-01
AU2016209332B2 (en) 2020-10-22

Similar Documents

Publication Publication Date Title
SI4070787T1 (sl) Farmacevtske formulacije
HK1254343A1 (zh) 藥物製劑
IL271226A (en) medical preparation
PT3426294T (pt) Formulação farmacêutica compreendendo anticorpo, ciclodextrina e metionina
IL253177A0 (en) Pharmacy preparation
HK1245653A1 (zh) 藥物製劑
ZA201707094B (en) Pharmaceutical formulations
IL266537A (en) pharmaceutical preparation
ZA201807851B (en) Pharmaceutical formulation
FI3601277T3 (fi) Farmaseuttinen formulaatio
GB201506755D0 (en) Novel pharmaceutical formulation
GB201511246D0 (en) Pharmaceutical formulation
PL3720424T3 (pl) Preparat farmaceutyczny
GB201719873D0 (en) Pharmaceutical formulation
GB201604545D0 (en) Novel pharmaceutical formulation